JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $37
JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target from $36 to $37.
Login to comment